SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
378.60
+4.45 (1.19%)
Jun 19, 2026, 3:29 PM IST
SMS Pharmaceuticals Revenue
In the fiscal year ending March 31, 2026, SMS Pharmaceuticals had annual revenue of 8.87B INR with 13.30% growth. SMS Pharmaceuticals had revenue of 2.38B in the quarter ending March 31, 2026, a decrease of -4.13%.
Revenue
8.87B
Revenue Growth
+13.30%
P/S Ratio
4.00
Revenue / Employee
6.03M
Employees
1,470
Market Cap
35.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.87B | 1.04B | 13.30% |
| Mar 31, 2025 | 7.83B | 734.85M | 10.36% |
| Mar 31, 2024 | 7.09B | 1.87B | 35.86% |
| Mar 31, 2023 | 5.22B | 21.77M | 0.42% |
| Mar 31, 2022 | 5.20B | -433.03M | -7.69% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 584.62B |
| Cipla | 278.28B |
| Apollo Hospitals Enterprise | 252.29B |
| Divi's Laboratories | 105.60B |
| Indraprastha Medical Corporation | 14.83B |
| Solara Active Pharma Sciences | 13.69B |
| Artemis Medicare Services | 10.81B |
| Medi Assist Healthcare Services | 9.05B |
SMS Pharmaceuticals News
- 14 days ago - SMS Pharmaceuticals uncovers fraudulent claim of 85,000 shares - Business Upturn
- 15 days ago - Pharma firm hit by Rs 3 cr shareholder fraud, case booked - The Times of India
- 6 months ago - SMS Pharmaceuticals successfully concludes USFDA inspection at Vizag API facility - Business Upturn
- 7 months ago - SMS Pharmaceuticals shares jump 4% as VKT Pharma secures US FDA approval for reformulated Ranitidine - Business Upturn
- 7 months ago - SMS Pharmaceuticals’ VKT Pharma receives US FDA approval for reformulated Ranitidine - Business Upturn
- 10 months ago - SMS Pharma shares surge over 7% after USFDA grants EIR for Hyderabad facility - Business Upturn
- 11 months ago - SMS Pharmaceuticals Q1 Results: Revenue jumps 19% YoY to Rs 196.05 crore, Net profit up14% YoY - Business Upturn
- 1 year ago - SMS Pharmaceuticals share jump 6% after its Hyderabad facility clears USFDA inspection with zero observations - Business Upturn